Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

Clicks: 583
ID: 266889
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #2 of 9 articles by views in journal of crohn's & colitis

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Higher vedolizumab serum concentrations were associated with higher remission rates after induction therapy in patients with moderately to severely active UC or CD. This relationship is affected by several factors, including previous TNFα antagonist use. Prospective studies are needed to assess vedo …
Reference Key
m2017journalexposure-efficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rosario M;French JL;Dirks NL;Sankoh S;Parikh A;Yang H;Danese S;Colombel JF;Smyth M;Sandborn WJ;Feagan BG;Reinisch W;Sands BE;Sans M;Fox I;;
Journal journal of crohn's & colitis
Year 2017
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.